Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy

被引:23
作者
Kitagawa, Y
Koshida, K
Mizokami, A
Komatsu, K
Nakashima, S
Misaki, T
Katsumi, T
Namiki, M
机构
[1] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Div Canc Med, Grad Sch Med, Kanazawa, Ishikawa 9208641, Japan
[2] Natl Kanazawa Hosp, Dept Urol, Kanazawa, Ishikawa 9208641, Japan
[3] Tonami Gen Hosp, Dept Urol, Tonami, Japan
关键词
biochemical recurrence; Japanese general rule; neoadjuvant therapy; pathological effect; prostate cancer;
D O I
10.1046/j.1442-2042.2003.00640.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: It is not clear whether pathological changes following neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy have any value as predictors of progression in prostate cancer. Methods: We conducted a study of 100 patients with prostate cancer who underwent radical prostatectomy following NHT. We used the Japanese general rule as the criterion to assess the biochemical recurrence rate and pathological changes after NHT. Results: In terms of preoperative risk factors, the probability of recurrence was significantly higher for patients with more than 20 ng/mL of pretreatment serum prostate-specific antigen (PSA) and/or a Gleason score of 7 or higher for biopsy specimens. We defined these pretreatment findings as high-risk factors. Among 65 patients with high-risk factors, patients with a post-NHT pathological effect of grade 3 according to the Japanese general rule showed no recurrence, whereas patients with a grade 0 had a poor prognosis. Patients with a PSA nadir 0.5 ng/mL or less tended to have a better prognosis. Conclusion: Despite preoperative high-risk factors, patients showing good pathological effects after NHT tend to have a favorable prognosis after radical prostatectomy. Therefore; assessment of the pathological effects of NHT using the Japanese general rule as the criterion proved to be useful for the prediction of biochemical recurrence.
引用
收藏
页码:377 / 382
页数:6
相关论文
共 27 条
[1]  
[Anonymous], 1997, TNM CLASSIFICATION M
[2]   CLINICAL AND PATHOBIOLOGICAL EFFECTS OF NEOADJUVANT TOTAL ANDROGEN ABLATION THERAPY ON CLINICALLY LOCALIZED PROSTATIC ADENOCARCINOMA [J].
ARMAS, OA ;
APRIKIAN, AG ;
MELAMED, J ;
CORDONCARDO, C ;
COHEN, DW ;
ERLANDSON, R ;
FAIR, WR ;
REUTER, VE .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (10) :979-991
[3]   Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: Results of a phase II study [J].
Cookson, MS ;
Sogani, PC ;
Russo, P ;
Sheinfeld, J ;
Herr, H ;
Dalbagni, G ;
Reuter, VE ;
Begg, CB ;
Fair, WR .
BRITISH JOURNAL OF UROLOGY, 1997, 79 (03) :432-438
[4]   Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer [J].
Dillioglugil, O ;
Leibman, BD ;
Kattan, MW ;
SealeHawkins, C ;
Wheeler, TM ;
Scardino, PT .
UROLOGY, 1997, 50 (01) :93-99
[5]   Supersensitive PSA-Monitored neoadjuvant hormone treatment of clinically localized prostate cancer:: Effects on positive margins, tumor detection and epithelial cells in bone marrow [J].
Enzmann, T ;
Feek, U ;
Köllermann, J ;
Kossiwakis, M ;
Kaulfuss, U ;
Martell, W ;
Spitz, J .
EUROPEAN UROLOGY, 1998, 34 (04) :318-324
[6]   Neoadjuvant therapy prior to radical prostatectomy: Pro [J].
Fair, WR ;
Garnick, MB .
UROLOGY, 1996, 48 (04) :535-538
[7]   The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results [J].
Fair, WR ;
Cookson, MS ;
Stroumbakis, N ;
Cohen, D ;
Aprikian, AG ;
Wang, Y ;
Russo, P ;
Soloway, SM ;
Sogani, P ;
Sheinfeld, J ;
Herr, H ;
Dalgabni, G ;
Begg, CB ;
Heston, WDW ;
Reuter, VE .
UROLOGY, 1997, 49 (3A) :46-55
[8]   Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up [J].
Gleave, ME ;
La Bianca, SE ;
Goldenberg, SL ;
Jones, EC ;
Bruchovsky, N ;
Sullivan, LD .
UROLOGY, 2000, 56 (02) :289-294
[9]   Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer [J].
Gleave, ME ;
Goldenberg, SL ;
Jones, EC ;
Bruchovsky, N ;
Sullivan, LD .
JOURNAL OF UROLOGY, 1996, 155 (01) :213-219
[10]   CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results [J].
Klotz, LH ;
Goldenberg, SL ;
Jewett, M ;
Barkin, J ;
Chetner, M ;
Fradet, Y ;
Chin, J ;
Laplante, S .
UROLOGY, 1999, 53 (04) :757-763